Mason W. Freeman

Mason W. Freeman

Chief Tech/Sci/R&D Officer at CINCOR PHARMA, INC.
75 year
Health Technology
Consumer Services
Health Services

Profile

Mason W.
Freeman
is currently the Director of Translational Medicine at The General Hospital Corp.
He is also a Venture Partner at 5AM Venture Management LLC and a Professor at Harvard Medical School.
Additionally, he holds the position of Chief Medical Officer at CinCor Pharma, Inc. starting in 2022.
In his former roles, Dr. Freeman served as a Director at Envoy Therapeutics, Inc. and Mitobridge, Inc. He was also a Director at scPharmaceuticals, Inc. from 2018 to 2020 and an Independent Director at Crinetics Pharmaceuticals, Inc. from 2015 to 2019.
Prior to that, he was the Head of Translational Medicine at Novartis AG from 2005 to 2007.
Dr. Freeman completed his undergraduate studies at Harvard University and obtained a doctorate degree from the University of California.

Mason W. Freeman active positions

CompaniesPositionStart
CINCOR PHARMA, INC. Chief Tech/Sci/R&D Officer 01/03/2022
Corporate Officer/Principal -
Corporate Officer/Principal -
Private Equity Investor 01/01/2008

Former positions of Mason W. Freeman

CompaniesPositionEnd
SCPHARMACEUTICALS INC. Director/Board Member 01/12/2020
CRINETICS PHARMACEUTICALS, INC. Director/Board Member 01/07/2019
Director/Board Member 01/01/2018
NOVARTIS AG Corporate Officer/Principal 01/04/2007
Director/Board Member -
See the detail of Mason W. Freeman's experience

Training of Mason W. Freeman

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

77

1st degree connections

11

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies11

Health Technology

Consumer Services

Health Services

Finance

Health Technology

Consumer Services

Consumer Services

Health Technology

Health Technology

Health Technology

Health Technology

  1. Stock Market
  2. Insiders
  3. Mason W. Freeman
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!